Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
University of Pennsylvania Identifier:
First received: February 24, 2015
Last updated: May 1, 2017
Last verified: May 2017
This is a triple cohort, open-label pilot study of the safety and antiviral activity of a single infusion of autologous CD4+ T cells genetically modified at the CCR5 gene by Zinc Finger Nucleases SB-728mR (ZFN Modified CD4+ T Cells) using electroporated mRNA with or without the prior administration of two different doses of cyclophosphamide.

Condition Intervention Phase
Human Immunodeficiency Virus (HIV)
Drug: ZFN Modified CD4+ T Cells
Drug: Cyclophosphamide
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 Delta-32 Mutation, Pre-treated With Cyclophosphamide

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Number of participants with adverse events [ Time Frame: 6 months post treatment ]

Estimated Enrollment: 15
Study Start Date: February 2015
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ZFN Modified CD4+ T Cell
ZFN Modified CD4+ T Cell
Drug: ZFN Modified CD4+ T Cells
Other Name: SB-728mR
Experimental: ZFN Modified CD4+ T Cell with Cyclophosphamide
ZFN Modified CD4+ T Cell with Cyclophosphamide
Drug: ZFN Modified CD4+ T Cells
Other Name: SB-728mR
Drug: Cyclophosphamide


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infection, as documented by a rapid HIV test or any FDA-approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western blot at any time prior to study entry or HIV antigen, plasma HIV-1 RNA, or second antibody test by a method other than rapid HIV and E/CIA. Alternatively, if a rapid HIV test or any FDA-approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit is not available, two HIV-1 RNA values ≥ 2000 copies/mL at least 24 hours apart performed by any laboratory that has CLIA certification, or its equivalent, may be used to document infection.
  • On a stable antiretroviral medication (no changes to treatment within 4 weeks of screening visit) and be willing to continue on current antiretroviral therapy for the duration of the study except for the duration of the 16 week analytical treatment interruption. NOTE: Subject's ART regimen must be in accordance with the Department of Health and Human Services Document "Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents."
  • CD4+ T cell count of ≥450 cells/mm3 at screen; and a documented CD4 nadir of not lower than 200 cells/mm3.
  • HIV-1 RNA undetectable by ultrasensitive assay copies/ml obtained at study screening visit or within 60 days prior to study screening visit performed with an ultrasensitive HIV-1 PCR assay.
  • All subjects must have received at least 18 months of therapy, and have had undetectable viral loads by ultrasensitive assay since month 6 of therapy. Subjects who had intermittent isolated episodes of detectable low-level viremia (detectable but < 500 copies RNA/mL; blips) will remain eligible.
  • Adequate venous access and no other contraindications for leukapheresis.
  • Laboratory values obtained at screen:

    1. Hemoglobin: ≥ 10.0 (males); ≥ 9.5 (females) g/dL
    2. Absolute neutrophil count (ANC): ≥ 1000/mm3
    3. Platelet count: ≥ 100,000/mm3
    4. Serum creatinine: ≤ 1.5 mg/dL (133μ mol/L)
    5. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT): ≤ 2.5 times the upper limit of normal (ULN).
  • Subjects must be willing to comply with study-mandated evaluations; including not changing their antiretroviral regimen (unless medically indicated) for 2 months in step 2 or until undergoing the analytical treatment interruption.
  • Be male or female, 18 years of age and older.
  • Ability and willingness of subject to provide informed consent.
  • Have a Karnofsky Performance Score of 70 or higher.
  • Have no polymorphisms in the CCR5 ZFN target region as determined by Cel I snp assay at screening.

Exclusion Criteria:

  • Acute or chronic hepatitis B or hepatitis C infection (as further defined in section 6.3.4 and 6.3.8 of this protocol)
  • Current or prior AIDS diagnosis.
  • History of cancer or malignancy, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin
  • History or any features on physical examination indicative of active or unstable cardiac disease or hemodynamic instability. NOTE: subjects with a history of cardiac disease may participate with a physician's approval.
  • History or any features on physical examination indicative of a bleeding diathesis.
  • Have been previously treated with any HIV experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector. Note: Subjects treated with placebo in an HIV vaccine study will not be excluded if documentation that they received placebo is provided.
  • Use of chronic systemic corticosteroids, hydroxyurea, or immunomodulating agents (e.g., interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to study screening visit. NOTE: Recent or current use of inhaled steroids is not exclusionary. If subjects are prescribed a brief course of oral corticosteroids, the use should be limited to less than 7 days. Use of steroids before apheresis and immune assessment blood draws should be discouraged as it will affect white blood cell function.
  • Breast-feeding, pregnant, or unwilling to use acceptable methods of birth control.
  • Use of aspirin, dyprydamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2-week period prior to leukapheresis.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study screening visit.
  • Asymptomatic baseline serum chemistry elevations in LFTs, bilirubin, lipase and serum creatinine due to HAART medication are not exclusionary, when in the opinion of the investigator, the abnormalities are not attributable to intrinsic hepatorenal disease. Such baseline elevations must be due to HAART.
  • Receipt of vaccination within 30 days prior to study screening visit. NOTE: It is recommended that subjects enrolling into this study should have completed their routine vaccinations (hepatitis A, hepatitis B, pneumococcus, and tetanus diphtheria booster) at least 30 days prior to screening for the study.
  • Have an allergy or hypersensitivity to study product excipients (human serum albumin, DMSO and Dextran 40).
  • CXCR4-tropic or R5/X4 dual-tropic HIV identified at screening using DNA tropism assay.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02388594

Contact: Pablo Tebas, MD 215-349-8091

United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Mark Bardsley    215-349-8092   
Contact: Joe Quinn    215-349-8092   
Sponsors and Collaborators
University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Responsible Party: University of Pennsylvania Identifier: NCT02388594     History of Changes
Other Study ID Numbers: SB-728mR
U01AI104400 ( US NIH Grant/Contract Award Number )
Study First Received: February 24, 2015
Last Updated: May 1, 2017

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists processed this record on May 22, 2017